News
TGTX
13.98
-1.89%
-0.27
Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)
TipRanks · 1d ago
Weekly Report: what happened at TGTX last week (0415-0419)?
Weekly Report · 2d ago
Health Care Sector Update for 04/18/2024: TGTX, ME, ELV, BNTC
NASDAQ · 6d ago
TG Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $45 Price Target
Benzinga · 6d ago
TG Therapeutics Price Target Maintained With a $25.00/Share by JP Morgan
Dow Jones · 6d ago
TG Therapeutics Price Target Maintained With a $39.00/Share by Ladenburg Thalmann
Dow Jones · 6d ago
JP Morgan Reiterates Overweight on TG Therapeutics, Maintains $25 Price Target
Benzinga · 6d ago
Ladenburg Thalmann Reiterates Buy on TG Therapeutics, Maintains $39 Price Target
Benzinga · 6d ago
TG Therapeutics wins VA contract for Briumvi
Seeking Alpha · 6d ago
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)
TipRanks · 6d ago
TG THERAPEUTICS ANNOUNCES ADDITIONAL DATA PRESENTATIONS FOR BRIUMVI® (UBLITUXIMAB-XIIY) IN MULTIPLE SCLEROSIS AT THE AMERICAN ACADEMY OF NEUROLOGY 2024 ANNUAL MEETING
Reuters · 6d ago
TG THERAPEUTICS INC - TOTAL AWARD AMOUNT OF CONTRACT HAS A POTENTIAL VALUE OF $186.8 MLN
Reuters · 6d ago
TG THERAPEUTICS AWARDED NATIONAL CONTRACT BY THE DEPARTMENT OF VETERANS AFFAIRS FOR BRIUMVI AS THE PREFERRED ANTI-CD20 FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS
Reuters · 6d ago
TG Therapeutics Inc Awarded $186,776,520 Contract From Department Of Veterans Affairs, NAC Pharmaceuticals For Pharmaceutical Preparation Manufacturing 6505--Anti CD20 Antibodies
Benzinga · 04/17 18:15
TG Therapeutics: The Cloud Over Briumvi
Seeking Alpha · 04/17 14:24
TG Therapeutics Becomes Oversold (TGTX)
NASDAQ · 04/15 20:55
Weekly Report: what happened at TGTX last week (0408-0412)?
Weekly Report · 04/15 11:52
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
TG Therapeutics, Inc. Presented data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The data will be presented at the 2024 American Academy of Neurology annual meeting in Denver, Colorado.
Barchart · 04/15 06:30
TG Therapeutics: BRIUMVI Development Could Lead To Great Results
TG Therapeutics launched its multiple sclerosis drug BRIUMVI in January 2023. The company has strong barriers to entry and patent protection for the drug. Hedge funds have started reinvesting in the company, indicating confidence in its future prospects. The share price seems expensive today, but the company has potential growth in 2024 and 2025.
Seeking Alpha · 04/12 22:17
More
Webull provides a variety of real-time TGTX stock news. You can receive the latest news about Tg Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.